ENXTPA:SANPharmaceuticals
Sanofi’s Venglustat Data Highlights Rare Disease Potential And Valuation Gap
Sanofi reported positive Phase 3 results for its investigational drug venglustat in type 3 Gaucher disease.
The study met its primary and most secondary endpoints, supporting plans for regulatory filings.
Venglustat targets neurological symptoms in GD3, an area with no approved therapies today.
For investors watching ENXTPA:SAN, this news sits against a mixed share price backdrop. The stock is trading at €80.36, with a 1.5% gain over the past week, a 2.9% decline over the past month, and an...